trending Market Intelligence /marketintelligence/en/news-insights/trending/gA1BG9qU7xxgozqS2U90nQ2 content esgSubNav
In This List

Alligator Bioscience inks China licensing deal with Biotheus

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Alligator Bioscience inks China licensing deal with Biotheus

Lund, Sweden-based Alligator Bioscience AB (publ) agreed to sell its right to an antibody in China to Biotheus Inc.

The Guangdong, China-based privately held drugmaker will pay Alligator an upfront payment of $1 million and as much as $142 million when certain milestones are achieved.

The total sum includes upfront and development milestones amounting to about $52 million, global option fees up to $90 million, plus royalties on future sales and share of sub-license revenue.

The agreement includes an option for expanding the license to cover global rights.

Biotheus can create up to three bispecific molecules based on the antibody. Bispecific molecules are drugs that target two types of antigens simultaneously.

Alligator Bioscience CEO Per Norlén said the deal gives the company an entry into the fast-growing life sciences market in China.